Alkeus Pharmaceuticals
PrivateLast Round
Series B
Jun 5, 2023
Total Funding Raised
$156.1M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Alkeus Pharmaceuticals is a biopharmaceutical company that develops innovative therapies for serious and untreatable eye diseases, including Stargardt disease and geographic atrophy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alkeus Pharmaceuticals Comparables
Compare Alkeus Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ascidian Therapeutics | 86% | |
| City Therapeutics | 84% | |
| Atsena Therapeutics | 84% |
Alkeus Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 5, 2023 | ||||
| Grant | Sep 26, 2018 | ||||
| Grant | Oct 22, 2013 | ||||
| Accelerator | Oct 1, 2010 |
Key People
Founding team and executive leadership
Alkeus Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bain Capital Life Sciences | Series B |
| TCG Crossover | Series B |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| MassChallenge Israel | Accelerator |
| Wellington Management | Series B |
| Food and Drug Administration | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors grew 69% MoM, from 3.8K to 6.4K.
- Mar 1, 2026
Lead compound ALK-001 granted breakthrough therapy and orphan drug status.
Recent news
Latest coverage and updates
- identified_as_competitor_ofAug 6, 2026
In Aug '26, the report identifies Alkeus Pharmaceuticals, Inc. as a competitor of Belite Bio, Inc. in Stargardt disease, with Alkeus Pharmaceuticals, Inc.'s gildeuretinol acetate trailing Belite Bio, Inc.'s tinlarebant, which reports phase 3 DRAGON data; NORTHSTAR top-line results are expected in 2029.
- receives_financingAug 6, 2026
Alkeus Pharmaceuticals, Inc. raises a $2M Series A round in 2011 after Leonide Saad uses his own money to fund the startup.
Alkeus Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Alkeus Pharmaceuticals's valuation, stock price, and market status.
Is Alkeus Pharmaceuticals a public or private company?
Alkeus Pharmaceuticals is a private company.
What is the current stock price of Alkeus Pharmaceuticals?
Alkeus Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Alkeus Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alkeus Pharmaceuticals worth (valuation)?
Valuation information for Alkeus Pharmaceuticals is not publicly available.
Can I buy Alkeus Pharmaceuticals stock?
Alkeus Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alkeus Pharmaceuticals's last funding round?
Alkeus Pharmaceuticals's most recent funding round was Series B on June 5, 2023.
Who are the main investors in Alkeus Pharmaceuticals?
Key investors in Alkeus Pharmaceuticals include Bain Capital Life Sciences.
Will Alkeus Pharmaceuticals IPO soon?
No public IPO plans have been announced for Alkeus Pharmaceuticals.
How can I track Alkeus Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Alkeus Pharmaceuticals's shares on secondary markets.